<- Go Home
Histogenics Corporation
As of September 27, 2019, Histogenics Corporation was acquired by Ocugen, Inc., in a reverse merger transaction. Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.
Market Cap
$4.5M
Volume
114.0K
Cash and Equivalents
$2.8M
EBITDA
-$19.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$85.80
52 Week Low
$1.95
Dividend
N/A
Price / Book Value
-0.51
Price / Earnings
-0.13
Price / Tangible Book Value
-0.51
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$20.0M
Return on Equity
16.69%
Return on Assets
-136.46
Cash and Short Term Investments
$2.8M
Debt
N/A
Equity
-$8.7M
Revenue
N/A
Unlevered FCF
-$21.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium